Date: 2015-11-05
Type of information: Nomination
Compound:
Company: RedXPharma (UK)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On November 5, 2015, Redx, the drug discovery and development company, announced two senior management appointments, with Nicholas Adams joining as Chief Business Officer and Dr Matilda Bingham\'s promotion to Executive Director of Redx Oncology Ltd, the Group\'s oncology subsidiary. Nicholas Adams\'s role as Chief Business Officer is a newly developed position and his appointment commences on 19 November. Nick has over 25 years\' experience in the pharmaceutical industry, and in particular in business development. He has led a wide range of deal types, including in- and out-licensing, divestments, royalty buy-outs as well as M&A. He has also worked in clinical development in large and mid-sized pharmaceutical companies and in biotech. Most recently, he was Chief Business Officer of Clavis Pharma ASA, the Norwegian drug development company specialising in oncology. Prior to that, he was Vice President of Business Development at Antisoma Research plc, which developed therapies for cancer and autoimmune disease. Dr Matilda Bingham has been appointed as Executive Director of Redx Oncology Ltd, with immediate effect, having served as Interim Managing Director of the subsidiary. She joined Redx in 2012 from MSD Research Laboratories, part of Merck & Co., Inc., where she led the medicinal chemistry teams. She has over 13 years of experience in the pharmaceutical industry, with a track record of delivering clinical development candidates.
Financial terms:
Latest news:
